ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / HUMA / earnings
OTLK (35) AVXL (32) ARMP (32) VYGR (15) ⌘ Pro Terminal →

Humacyte Inc. (HUMA) Next Earnings Date & Expected ±12.5% Move

$0.40 -3.19% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.40

Humacyte Inc. (HUMA) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $114.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HUMA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is HUMA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Humacyte Inc. (NASDAQ: HUMA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $0.40 (-3.19% 1D, market cap $114.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, HUMA ranks #800 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does HUMA compare to OTLK and AVXL in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), HUMA carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, OTLK (Outlook Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $114.0M) and AVXL (Anavex Life Sciences Corp.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $110.3M). Among the 5-stock peer group, HUMA leads on earnings multiple (N/A) while HUMA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HUMA?
▼

Per HUMA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001818382), Humacyte Inc. generated $2.0M in revenue (-99.4% YoY), -$40.8M in net income, and -$105.9M in free cash flow against $116.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.40 (-0.76%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510030
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (4)Whales (10)SEC (8)Macro (5)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.5% Base Target
$2 Bull$0 Base$0 Bear
📬 FREE HUMA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HUMA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY HUMA SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (33% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
22
Grade E$0.36+13.9% Next Q
Q2 (-2Q)
25
Grade E$0.41+9.8% Next Q
Q3 (-1Q)
27
Grade E$0.45-11.1% Next Q
Current
30
Grade E$0.40-9.6% Hist 90D α
Trajectory: E (22) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a HUMA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While HUMA currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.52) and Max Pain ($0.42) forces dealer call-delta covering toward $1.76.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HUMA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “HUMA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 30%NO 70%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.05 Expected Swing
$1.00 (-12.5%)Spot $0.40$0.45 (+12.5%)
MODEL EARNINGS SETUP GAUGE

HUMA Quantitative Pre-Earnings Setup: 30/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (30/100)Model Risk Weight (70/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$2.0M-$40.8M-$105.9M-50%
FY 20242024-12-31$320.3M-$148.7M-$99.7M8%
FY 20232023-12-31$280.1M-$110.8M-$73.3M8%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HUMA)

  • ✓Walkthrough of HUMA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
HUMA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -56.99%⚡ TESTING RESISTANCE
2026-11-03O $0.47H $0.47L $0.40C $0.40VOL 5.12M
RES: $0.50SUP: $0.27SMA50: $0.52SMA200: $0.80
$1.60$1.26$0.92$0.58$0.23RES $0.50SUP $0.27$0.402026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HUMA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HUMA Butterfly Map → + Track HUMA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -99.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on HUMA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HUMA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for HUMA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HUMA)

Health Care Rank #800 of 1015 ⚔️ OTLK vs HUMA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HUMA vs. OTLK, AVXL, ARMP, VYGR)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Humacyte Inc. (HUMA) ranks #800 by composite RQD confidence (30/100, grade E) and #632 by equity capitalization ($114.2M). Within this direct 5-issuer industry benchmark cohort, HUMA leads on earnings valuation at N/A trailing P/E, while HUMA leads on capital efficiency and profitability with -35.0% ROIC and -30.0% gross margin. OTLK currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with HUMA at 30/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
HUMA ACTIVE
Humacyte Inc.
E 30/100 — -30.0% -35.0% -3.19% $114.2M Benchmark Subject
OTLK
Outlook Therapeutics Inc.
D- 35/100 — 4.0% -35.0% +0.24% $114.0M /otlk-vs-huma →
AVXL
Anavex Life Sciences Corp.
E 32/100 — — -35.0% -4.20% $110.3M /avxl-vs-huma →
ARMP
Armata Pharmaceuticals Inc.
E 32/100 — — -35.0% -13.11% $122.0M /armp-vs-huma →
VYGR
Voyager Therapeutics Inc.
E 15/100 — — -35.0% +3.49% $106.0M /vygr-vs-huma →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001818382 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Humacyte Inc. (HUMA) reported GAAP revenue of $2.0M (-99.4% vs. FY2024 revenue of $320.3M , and -99.3% cumulative change since FY2023) , GAAP net income of -$40.8M, operating cash flow of -$105.0M, and free cash flow of -$105.9M (-6.3% YoY). On the balance sheet, HUMA closed FY2025 with $116.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $2.0M -$40.8M -$105.0M -$105.9M $116.4M —
FY2024 (FY) 2024-12-31 $320.3M -$148.7M -$98.1M -$99.7M $137.9M —
FY2023 (FY) 2023-12-31 $280.1M -$110.8M -$73.3M -$73.3M — —

3. HUMA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HUMA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Humacyte Inc. (NASDAQ: HUMA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $0.40 (-3.19% 1D, market cap $114.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, HUMA ranks #800 in composite RQD confidence.

How does HUMA compare to OTLK and AVXL in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), HUMA carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, OTLK (Outlook Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $114.0M) and AVXL (Anavex Life Sciences Corp.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $110.3M). Among the 5-stock peer group, HUMA leads on earnings multiple (N/A) while HUMA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for HUMA?

Per HUMA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001818382), Humacyte Inc. generated $2.0M in revenue (-99.4% YoY), -$40.8M in net income, and -$105.9M in free cash flow against $116.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is HUMA trading relative to its 50-day, 200-day, and 52-week technical levels?

HUMA last traded at $0.40 (-3.19% on volume of 5,214,447 shares), positioning the stock -23.08% below its 50-day simple moving average ($0.52) and -50.00% below its 200-day simple moving average ($0.80). Across its 52-week range of $0.34 to $1.68, HUMA sits at the 4.5% percentile with a 14-day RSI of 43.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.45).

Direct Sub-Reports: HUMA RQD Cockpit HUMA 12M Forecast HUMA Earnings & Move HUMA Dividends & DRIP HUMA Insiders & 13F HUMA Whale Options HUMA Profit Sankey HUMA News & Why
ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ SEC XBRL & RQD VERIFIED

HUMA — Humacyte Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Humacyte Inc. (HUMA) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.40 (-3.19% 1D, market capitalization $114.2M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of -30.0%, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (10/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Humacyte Inc. (HUMA) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. The market capitalization is $0.1B. FY 2025 revenue was $2.0M. — describes its specific products, customers, or revenue model.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Humacyte Inc. (HUMA) reported $2.0M in annual revenue (up from $320.3M in FY2024, -99.4% YoY) and -$40.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($280.1M revenue, -$110.8M net income) through FY2025, HUMA scaled operating cash flow to -$105.0M and free cash flow to -$105.9M, backed by $116.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 30/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 10/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $0.34 – $1.68 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector-level context available is the Health Care classification and the beta of 1.0.

  • Key Question #1: Can HUMA sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $2.0M and free cash flow of -$105.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is HUMA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

HUMA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Humacyte Inc. (HUMA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to HUMA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

HUMA Bull vs. Bear Conversation Board — What's Your Call at $0.40?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HUMA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on HUMA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $0.48 (+17.1%)
📌 Pinned Debate

The news wire reports 49 hospitals ordering the bioengineered blood vessel, with H.C. Wainwright reiterating a Buy.

Here is why I am bullish on HUMA here at $0.41: The news wire reports 49 hospitals ordering the bioengineered blood vessel, with H.C. Wainwright reiterating a Buy.. Compare HUMA's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Biological Products (No Diagnostic Substances). As long as cash conversion holds up, dips toward $0.39 are getting bought.

RetailWhale_TX 🐂 BULL

Both sides have a point here — HUMA's 8/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $0.35 (-14.6%)
Spot @ $0.41

FY 2025 free cash flow of -$105.9M against $50.5M in cash, with an RQD score of 31 and a Piotroski F-Score of 2/9.

I respect the product at Humacyte Inc., but the stock at $0.41 is a different story. FY 2025 free cash flow of -$105.9M against $50.5M in cash, with an RQD score of 31 and a Piotroski F-Score of 2/9.. FCF yield is 0.0% and RQD sits at 30/100 (E) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%